Assenagon Asset Management
LUMO

Assenagon Asset Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Assenagon Asset Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,602
Closed -$35K – 1108
2019
Q2 		$35K Buy
+2,602
New +$39.3K ﹤0.01% 976

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management's LUMO Position: Q3 2019 in Review

Assenagon Asset Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2019, closing a stake of 2,602 shares — an estimated $35K sold.

Assenagon Asset Management first reported a position in LUMO in Q2 2019 and held it in 1 quarter. The position peaked at $35K in Q2 2019. 68 funds tracked by Wall St. Rank hold LUMO as of Q3 2019.

  • Assenagon Asset Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 2,602 Lumos Pharma, Inc. Common Stock shares in Q3 2019, an estimated $35K.
  • Assenagon Asset Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Assenagon Asset Management's Lumos Pharma, Inc. Common Stock position peaked at $35K in Q2 2019.
  • 68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2019.

Based on Assenagon Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.